Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan
This prospective postmarketing surveillance study confirms the effectiveness and manageable safety profile of alemtuzumab for Japanese patients with relapsed/refractory CLL.
Authors
- Kenichi Ishizawa (ORCID: https://orcid.org/0000-0003-4911-8889)
- M. Hatanaka (ORCID: https://orcid.org/0009-0008-2733-8382)
- Yukie Sasakura
Institutions
- Tohoku Fukushi University (JP)
- Sanofi (Japan) (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1093/jjco/hyaf044
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi